Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

NCT: NCT05064540 · RECRUITING

NCT IDNCT05064540
StatusRECRUITING
Start Date2021-09-20
Completion2032-03
SponsorEndologix (INDUSTRY)
First posted
Last updated

Brief Summary

Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).

Frequently Asked Questions

What is JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization?

JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization is a clinical trial registered under NCT05064540. Current status: RECRUITING.

What is the status of NCT05064540?

The current status of NCT05064540 (JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization) is: RECRUITING.

When did JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization start?

JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization started on 2021-09-20.

Related Devices

PMA P040002SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENTEndologix, LLC PMA P120006SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENTEndologix, LLC PMA P220021Stent graft, bypass, superficial femoral arteryEndologix, LLC

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑